EQS.PA Equasens S. A.

Healthcare Health Care Technology Euronext Paris
27.80 EUR
Close of Nov 8, 2026
25.55 43.51
Market cap
EUR 418M
P/E
10.7x
P/B
1.67x
ROE
30.4%
Dividend yield
2.49%
Fundamental score
4.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is EQS.PA undervalued?

Graham number
Price27.80
Graham value31.13
Discount10.7%

EQS.PA trades 10.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Equasens S. A. fundamental analysis

9 of 11 checks passed

ROE 2/2

ROE surpassing expectations (26.59%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

ROA 2/2

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

PBV 0/2

The stock's high Price-to-Book Value (P/BV) ratio (4.59x) suggests it's overvalued, potentially making it an expensive investment.

DER 2/2

The stock has a minimal amount of debt (10%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 2/2

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

Net Profit Growth 2/2

The net profit of this company has steadily increased over the last five years, showcasing a favorable financial performance and making it an enticing option for investors seeking growth potential.

Assets Growth 2/2

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

Graham Number 0/1

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

Dividend Growth 2/2

Investors can be encouraged by the company's strong dividend growth over the past five years, highlighting its ability to generate consistent returns and provide an attractive investment opportunity.

Dividend 2/2

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

Buffet Intrinsic Value 1/1

The company's stock presents an enticing opportunity as it appears undervalued (311) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Equasens S. A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Equasens S. A.

Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments. The company engages in publishing and distribution of pharmacy, practice, management software and related offerings for pharmacies, medical-social establishments, doctors, and medical auxiliaries; dist…

Full company profile